Key result
The Siemens Atellica hs-cTnI 0-1 hour rule-out algorithm achieved 100% sensitivity and NPV with >70% specificity for NSTEMI, comparable to established Roche and Abbott assays.
Why the study?
The accuracy for early identification of NSTEMI in the emergency department must be determined for all novel hs-cTn assays, requiring development and validation of rule-out algorithms for the Siemens Atellica IM hs-cTnI assay.
Does the Siemens Atellica IM hs-cTnI rule-out algorithm provide comparable diagnostic accuracy to established hs-cTnT and hs-cTnI algorithms for early rule-out of NSTEMI in emergency department patients?
Cohort (n=1,900)
Yes
Does the Siemens Atellica IM hs-cTnI rule-out algorithm provide comparable diagnostic accuracy to established hs-cTnT and hs-cTnI algorithms for early rule-out of NSTEMI in emergency department patients?
Rule-out algorithms utilizing the novel Siemens Atellica IM hs-cTnI assay provide diagnostic accuracy comparable to established Roche hs-cTnT and Abbott hs-cTnI algorithms for early identification and rule-out of NSTEMI in the emergency department.
Answers are grounded in this paper and cite their sources.
May support Siemens hs-cTnI 0–1 h rule-out of NSTEMI; leaves open prospective validation before practice change.
Background The accuracy for early identification of non-ST-elevation myocardial infarction (NSTEMI) in the emergency department must be determined for all novel high-sensitivity cardiac troponin assays (hs-cTn). In this prospective, multi-centre study we developed rule-out algorithms for a high-sensitivity cardiac troponin I (hs-cTnI) assay and compared it to established algorithms for hs-cTnT and hs-cTnI. Methods Two rule-out algorithms for NSTEMI were developed from a derivation cohort of 977 patients assessed by the Siemens Atellica IM hs-cTnI assay. Diagnostic performance was compared with hs-cTnT (Roche) and hs-cTnI (Abbott) algorithms. The derived algorithms were tested in two different validation cohorts (n=518 and n=405, respectively). Results An admission sample algorithm (hs-cTnI (Siemens)) for rule-out of NSTEMI with cutoff <5 ng/L had negative predictive value (NPV) 99.4–100.0%, sensitivity 98.3–100% and specificity 46.7–56.5% in the two validation cohorts. Sensitivity and NPV was similar, specificity trended towards improvement over the comparator algorithms (Figure 1). A 0–1 hour algorithm (hs-cTnI (Siemens)) with cutoff <10 ng/L and Δ change <3 ng/L achieved sensitivity and NPV 100% with specificity >70% in both validation cohorts, similar to the comparator algorithms (Table 1). Conclusions Rule-out algorithms from the Siemens Atellica hs-cTnI assay has comparable diagnostic accuracy to established hs-cTn rule-out algorithms. Funding Acknowledgement Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Public grant: Western Norway Regional Health Authority.
No takes yet. Share an insight, caveat, or question.
Restan et al. (2022) conducted a cohort in Suspected non-ST-elevation myocardial infarction (NSTEMI) (n=1,900). Siemens Atellica IM hs-cTnI rule-out algorithms (admission <5 ng/L; 0-1 hour <10 ng/L and delta <3 ng/L) vs. Established hs-cTnT (Roche) and hs-cTnI (Abbott) rule-out algorithms was evaluated on Diagnostic accuracy (sensitivity, negative predictive value, and specificity) for rule-out of NSTEMI. The Siemens Atellica hs-cTnI 0-1 hour rule-out algorithm achieved 100% sensitivity and NPV with >70% specificity for NSTEMI, comparable to established Roche and Abbott assays.
Synapse has enriched 10 related papers. Consider them for comparative context: